Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
A Telephone-Based Education and Prevention Intervention for Teens and Young Adults
Verified date | February 2017 |
Source | Georgetown University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Telephone-based cancer education and counseling may help participants learn about
ways of preventing cancer and choose a lifestyle that will help them stay healthy as they
grow older.
PURPOSE: This randomized clinical trial is studying telephone-based cancer education and
telephone-based counseling to see how well they work compared with telephone-based cancer
education alone in young participants.
Status | Completed |
Enrollment | 104 |
Est. completion date | December 2010 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 13 Years to 21 Years |
Eligibility |
DISEASE CHARACTERISTICS: - No life-threatening illness (e.g., cancer) - Chronic illnesses (e.g., asthma, diabetes) allowed with permission by physician PATIENT CHARACTERISTICS: - No serious restrictions on physical activity, diet, or nutrition, including any of the following: - Untreated exercise-induced asthma - Orthopedic or neurological problems - Medical conditions affecting nutritional status, intestinal absorption, or response to nutritional intervention (e.g., inflammatory bowel disease) - No serious mental illness or developmental disability that would preclude study compliance, including eating disorders - Must adequately understand, speak, and read English PRIOR CONCURRENT THERAPY: - Not specified |
Country | Name | City | State |
---|---|---|---|
United States | Lombardi Comprehensive Cancer Center at Georgetown University Medical Center | Washington, D.C. | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Georgetown University | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Multiple risk factor index | 6 months | ||
Primary | Knowledge | 6 months | ||
Primary | Health history taking | 3 months | ||
Primary | Nutrition | 6 months | ||
Primary | Physical activity | 6 months | ||
Primary | Tobacco use intentions and behavior | 6 months | ||
Primary | Alcohol use intentions and behavior | 6 months | ||
Primary | Screening intentions | 6 months | ||
Primary | Self-efficacy | 6 months | ||
Primary | Perceived benefits | 6 months | ||
Primary | Perceived barriers | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00387920 -
Sunitinib in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00176540 -
Dextromethorphan in Treating Patients With Fatigue Caused by Cancer
|
N/A | |
Completed |
NCT00070473 -
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
|
Phase 1 |